In line with this, sulfonylurea treatment is associated with weight gain and increased risk for hypoglycaemia, whereas metformin and SGLT2 inhibitors are associated with weight loss and low risk of hypoglycaemia.6 This evidence concerns the gene SLC5A2 and Hypoglycemia.